Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Gi-Ae | - |
dc.contributor.author | Han, Seungbong | - |
dc.contributor.author | Choi, Gwang Hyeon | - |
dc.contributor.author | Choi, Jonggi | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.date.available | 2020-07-02T04:36:36Z | - |
dc.date.created | 2020-04-28 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/60204 | - |
dc.description.abstract | Background Studies have shown a higher risk of hepatocellular carcinoma (HCC) with higher baseline serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. However, the association between very high HBV DNA levels (>6 log(10) IU/mL) and HCC risk remains unclear, especially in middle-aged and old HBeAg-positive patients. Aim To identify the association between broad-range HBV DNA levels and HCC risk. Methods We conducted a historical cohort study in Korea involving 6949 non-cirrhotic, treatment-naive CHB patients with alanine aminotransferase (ALT) 1 year. HBV DNA was >6 log(10) IU/mL in 2029 (29.2%) patients. Follow-up was censored when the antiviral therapy was initiated. Results The mean age of the patients was 45 years. During 8.0 years of median follow-up, 363 patients (5.2%) developed HCC. By multivariable Cox regression analysis, HCC risk was highest with baseline HBV DNA levels of 6-7 log(10) IU/mL (adjusted hazard ratio [aHR] 4.98; P < 0.001), and lowest with >8 log(10) IU/mL (aHR 0.90; P = 0.71) and <= 4 log(10) IU/mL (aHR 1.00; reference), which was independent of other predictive factors. The similar association between HBV DNA levels and HCC risk was consistently observed in all age subgroups (age <40, 40-49 and >= 50 years). Conclusions HCC risk was highest with moderate serum HBV DNA levels of 6-7 log(10) IU/mL in CHB patients without significant ALT elevation. Extending treatment indication to CHB patients with moderate levels of HBV DNA may be considered to further prevent HCC, regardless of ALT levels. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.title | Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000525811000001 | - |
dc.identifier.doi | 10.1111/apt.15725 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85083434561 | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.contributor.affiliatedAuthor | Han, Seungbong | - |
dc.type.docType | Article; Early Access | - |
dc.subject.keywordPlus | TENOFOVIR DISOPROXIL FUMARATE | - |
dc.subject.keywordPlus | HBV DNA | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | HEPATOCYTES | - |
dc.subject.keywordPlus | ALAFENAMIDE | - |
dc.subject.keywordPlus | INTEGRATION | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.